{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:17:01Z","timestamp":1781795821932,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.endinu.2016.11.001","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T11:01:56Z","timestamp":1487242916000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S1","title":["Recomendaciones sobre el efecto de los f\u00e1rmacos antidiab\u00e9ticos en el hueso"],"prefix":"10.1016","volume":"64","author":[{"given":"Pedro","family":"Rozas-Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Reyes-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"J\u00f3dar-Gimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariela","family":"Varsavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Luque-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Cort\u00e9s-Berdonces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mu\u00f1oz-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.endinu.2016.11.001_bib0215","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1359\/jbmr.080323","article-title":"Fracture risk in type2 diabetes: Update of a population-based study","volume":"23","author":"Melton","year":"2008","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.endinu.2016.11.001_bib0220","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00125-005-1786-3","article-title":"Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk","volume":"48","author":"Vestergaard","year":"2005","journal-title":"Diabetologia."},{"key":"10.1016\/j.endinu.2016.11.001_bib0225","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","article-title":"Rosiglitazone-associated fractures in type2 diabetes: An Analysis from A Diabetes Outcome Progression Trial (ADOPT)","volume":"31","author":"Kahn","year":"2008","journal-title":"Diabetes Care."},{"key":"10.1016\/j.endinu.2016.11.001_bib0230","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1210\/jc.2009-0572","article-title":"Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type2 diabetes","volume":"95","author":"Zinman","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endinu.2016.11.001_bib0235","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1463-1326.2011.01461.x","volume":"13","author":"Borges","year":"2011","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.endinu.2016.11.001_bib0240","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11914-010-0027-y","article-title":"Bone loss in diabetes: Use of antidiabetic thiazolidinediones and secondary osteoporosis","volume":"8","author":"Lecka-Czernik","year":"2010","journal-title":"Osteoporos Rep."},{"key":"10.1016\/j.endinu.2016.11.001_bib0245","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s00125-015-3660-2","article-title":"The effect of thiazolidinediones on bone mineral density and bone turnover: Systematic review and meta-analysis","volume":"58","author":"Billington","year":"2015","journal-title":"Diabetologia."},{"key":"10.1016\/j.endinu.2016.11.001_bib0250","doi-asserted-by":"crossref","first-page":"e0135530","DOI":"10.1371\/journal.pone.0135530","article-title":"Glycemic control with thiazolidinedione is associated with fracture of T2DM patients","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.endinu.2016.11.001_bib0255","unstructured":"McCulloch DK. Thiazolidinediones in the treatment of diabetes mellitus DW. En: UpToDate, Nathan DM TW (Ed), UpToDate, Waltham, MA [consultado 20 Oct 2015]. http:\/\/www.uptodate.com\/contents\/thiazolidinediones-in-the-treatment-of-diabetes-mellitus."},{"key":"10.1016\/j.endinu.2016.11.001_bib0260","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1210\/jc.2015-1215","article-title":"Effects of TZD use and discontinuation on fracture rates in ACCORD bone study","volume":"100","author":"Schwartz","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endinu.2016.11.001_bib0265","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1503\/cmaj.080486","article-title":"Long-term use of thiazolidinediones and fractures in type2 diabetes: A meta-analysis","volume":"180","author":"Loke","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.endinu.2016.11.001_bib0270","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0377-1237(11)60120-2","article-title":"Evaluation of bone mineral density in type2 diabetes mellitus patients before and after treatment","volume":"68","author":"Dutta","year":"2012","journal-title":"Med J Armed Forces India."},{"key":"10.1016\/j.endinu.2016.11.001_bib0275","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00774-010-0160-9","article-title":"Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type2 diabetes mellitus","volume":"28","author":"Kanazawa","year":"2010","journal-title":"J Bone Miner Metab."},{"key":"10.1016\/j.endinu.2016.11.001_bib0280","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40266-013-0081-0","article-title":"Sulfonylureas and risk of falls and fractures: A systematic review","volume":"30","author":"Lapane","year":"2013","journal-title":"Drugs Aging."},{"key":"10.1016\/j.endinu.2016.11.001_bib0285","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.diabres.2015.05.009","article-title":"Sulfonylureas and risk of falls and fractures among nursing home residents with type2 diabetes mellitus","volume":"109","author":"Lapane","year":"2015","journal-title":"Diabetes Res Clin Pract."},{"key":"10.1016\/j.endinu.2016.11.001_bib0290","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40266-015-0254-0","article-title":"Sulfonylurea use and risk of hip fractures among elderly men and women with type2 diabetes","volume":"32","author":"Rajpathak","year":"2015","journal-title":"Drugs Aging."},{"key":"10.1016\/j.endinu.2016.11.001_bib0295","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.endinu.2016.11.001_bib0300","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bone.2014.07.030","article-title":"Use of dipeptidyl peptidase-4 inhibitors for type2 diabetes mellitus and risk of fracture","volume":"68","author":"Driessen","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.endinu.2016.11.001_bib0305","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/dc11-1099","article-title":"Dipeptidyl peptidase-4 inhibitors and bone fractures: A meta-analysis of randomized clinical trials","volume":"34","author":"Monami","year":"2011","journal-title":"Diabetes Care."},{"key":"10.1016\/j.endinu.2016.11.001_bib0310","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1210\/jc.2015-4180","article-title":"Does Sitagliptin affect the rate of osteoporotic fractures in type 2 diabetes? Population-based cohort study","volume":"101","author":"Majumdar","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endinu.2016.11.001_bib0315","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1463-1326.2010.01355.x","article-title":"Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type2 diabetes","volume":"13","author":"Bunck","year":"2011","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.endinu.2016.11.001_bib0320","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4158\/EP15758.OR","article-title":"Comparison of the long-term effects of liraglutide and glimepiride monotherapy on bone mineral density in patients with type2 diabetes","volume":"22","author":"Gilbert","year":"2016","journal-title":"Endocr Pract."},{"key":"10.1016\/j.endinu.2016.11.001_bib0325","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/1753-0407.12102","article-title":"Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials","volume":"6","author":"Mabilleau","year":"2014","journal-title":"J Diabetes."},{"key":"10.1016\/j.endinu.2016.11.001_bib0330","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12020-014-0361-4","article-title":"Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists\u2019 treatment: A meta-analysis of randomized controlled trials","volume":"48","author":"Su","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.endinu.2016.11.001_bib0335","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00223-015-9993-5","article-title":"Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: A population-based cohort analysis","volume":"97","author":"Driessen","year":"2015","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.endinu.2016.11.001_bib0340","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s00223-015-0037-y","article-title":"Use of glucagon-like-peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs","volume":"97","author":"Driessen","year":"2015","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.endinu.2016.11.001_bib0345","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endinu.2016.11.001_bib0350","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endinu.2016.11.001_bib0355","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","article-title":"Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type2 diabetes mellitus on metformin","volume":"14","author":"Ljunggren","year":"2012","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.endinu.2016.11.001_bib0360","unstructured":"Jardiance Public Assessment Report. European Medicines Agency [consultado 15 Abr2016]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Public_assessment_report\/human\/002677\/WC500168594.pdf"},{"key":"10.1016\/j.endinu.2016.11.001_bib0365","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40264-014-0213-4","article-title":"Safety profile of dapagliflozin for type 2 diabetes: Pooled analysis of clinical studies for overall safety and rare events","volume":"37","author":"Ptaszynska","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.endinu.2016.11.001_bib0370","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.endinu.2016.11.001_bib0375","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endinu.2016.11.001_bib0380","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"Suppl","key":"10.1016\/j.endinu.2016.11.001_bib0385","first-page":"S205A","article-title":"No increase in bone fractures with empagliflozin (EMPA) in a pooled analysis of more than 11,000 patients with type 2 diabetes (T2DM) (abstract)","volume":"24","author":"Wanner","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.endinu.2016.11.001_bib0390","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00198-005-0013-x","article-title":"Diabetes mellitus and the risk of non-vertebral fractures: The Troms\u00f8 study","volume":"17","author":"Ahmed","year":"2006","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.endinu.2016.11.001_bib0395","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2337\/diacare.24.7.1192","article-title":"Type1 and type2 diabetes and incident hip fractures in postmenopausal women","volume":"24","author":"Nicodemus","year":"2001","journal-title":"Diabetes Care."},{"key":"10.1016\/j.endinu.2016.11.001_bib0400","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diacare.24.7.1198","article-title":"Diabetes and risk of fracture: The Blue Mountains Eye Study","volume":"24","author":"Ivers","year":"2001","journal-title":"Diabetes Care."},{"key":"10.1016\/j.endinu.2016.11.001_bib0405","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/jcem.86.1.7139","article-title":"Older women with diabetes have an increased risk of fracture: A prospective study","volume":"86","author":"Schwartz","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endinu.2016.11.001_bib0410","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2337\/dc07-1736","article-title":"Bone fractures and hypoglycemic treatment in type2 diabetic patients: A case-control study","volume":"31","author":"Monami","year":"2008","journal-title":"Diabetes Care."},{"key":"10.1016\/j.endinu.2016.11.001_bib0415","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/archinte.165.14.1612","article-title":"Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: The health, aging, and body composition study","volume":"165","author":"Strotmeyer","year":"2005","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.endinu.2016.11.001_bib0420","unstructured":"Rozas-Moreno P, Reyes-Garc\u00eda R, J\u00f3dar-Gimeno E, Varsavsky M, Luque-Fern\u00e1ndez I, Cort\u00e9s-Berdonces M, et al. Recomendaciones sobre el efecto de los f\u00e1rmacos antidiab\u00e9ticos en el hueso. Grupo de Trabajo de Osteoporosis y Metabolismo \u00d3seo de la Sociedad Espa\u00f1ola de Endocrinolog\u00eda y Nutrici\u00f3n. Disponible en: http:\/\/www.seen.es\/herramientasClinicas\/guias\/seen\/guiaSeen.aspx"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016416300064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016416300064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T22:51:32Z","timestamp":1636239092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530016416300064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":42,"alternative-id":["S2530016416300064"],"URL":"https:\/\/doi.org\/10.1016\/j.endinu.2016.11.001","relation":{},"ISSN":["2530-0164"],"issn-type":[{"value":"2530-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recomendaciones sobre el efecto de los f\u00e1rmacos antidiab\u00e9ticos en el hueso","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 SEEN. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}